

# FEE TRANSMITTAL for FY 2005

Effective 12/08/2004. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$)**180.00**

## Complete if Known

Application Number **09/902,572**  
Filing Date **July 10, 2001**  
First Named Inventor **Ashkenazi, et al.**  
Examiner Name **Sullivan, Daniel**  
Art Unit **1636**  
Attorney Docket No. **39780-1618P2C40**

## METHOD OF PAYMENT (check one)

☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit Account Number **08-1641 (Docket No. 39780-1618P2C40)**

Deposit Account Name **Heller Ehrman, LLP**

The Commissioner is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☒ Credit any overpayments  
☒ Charge any additional fee(s) during the pendency of this application  
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
1001	300	2001	150	Utility filing fee	
1002	350	2002	175	Design filing fee	
1003	550	2003	275	Plant filing fee	
1004	790	2004	395	Reissue filing fee	
1005	200	2005	100	Provisional filing fee	

SUBTOTAL (1) (\$)

### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
<input type="text"/>	-20** = <input type="text"/>	x <input type="text"/>	= <input type="text"/>
Independent Claims	-3** = <input type="text"/>	x <input type="text"/>	= <input type="text"/>
Multiple Dependent			= <input type="text"/>

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description
1202	50	2202	25	Claims in excess of 20
1201	200	2201	100	Independent claims in excess of 3
1203	360	2203	180	Multiple dependent claim, if not paid
1204	200	2204	100	**Reissue independent claims over original patent
1205	50	2205	25	**Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Fee Code	Entity Fee (\$)	Small Fee Code	Entity Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for <i>ex parte</i> reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	120	2251	60	Extension for reply within first month	
1252	450	2252	225	Extension for reply within second month	
1253	1,020	2253	510	Extension for reply within third month	
1254	1,590	2254	795	Extension for reply within fourth month	
1255	2,160	2255	1,080	Extension for reply within fifth month	
1401	500	2401	250	Notice of Appeal	
1402	500	2402	250	Filing a brief in support of an appeal	
1403	1,000	2403	500	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	500	2452	250	Petition to revive - unavoidable	
1453	1,500	2453	750	Petition to revive - unintentional	
1501	1,400	2501	700	Utility issue fee (or reissue)	
1502	800	2502	400	Design issue fee	
1503	1,100	2503	550	Plant issue fee	
1460		1460		Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	790	2809	395	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	790	2810	395	For each additional invention to be examined (37 CFR 1.129(b))	
1801	790	2801	395	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

\* Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)**180.00**

## SUBMITTED BY


Name (Print/Type)	Registration No. (Attorney/Agent)	Telephone
<b>PANPAN GAO</b>	<b>43,626</b>	<b>650-324-7000</b>
Signature	Date	Customer No.
	<b>September 19, 2005</b>	<b>35489</b>

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop 1, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

BEST AVAILABLE COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant: Ashkenazi, et al. Docket No.: 39780-1618P2C40  
Serial No.: 09/902,572 Group Art Unit: 1636  
Filing Date: July 10, 2001 Examiner: Sullivan, Daniel  
For: Secreted and Transmembrane Polypeptides and Nucleic Acids Encoding the Same

EXPRESS MAIL LABEL NO.: EL 976 550 625 US

DATE MAILED: September 19, 2005

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §1.97**

**MS: AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Listed on an attached Form PTO-1449 is information known to applicant(s). A copy is provided of each foreign patent; each publication other than U.S. patents and U.S. patent application publications, and each cited pending unpublished U.S. application along with a concise explanation of information in a foreign language pursuant to 37 C.F.R. §§1.97-1.98.

A copy of each reference is provided herewith. Applicants submit these documents to ensure that all references are of record and considered in all related applications. Applicants respectfully request the Examiner to acknowledge consideration of the currently submitted references by initialing and returning form PTO-1449 in accordance with MPEP §609.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

☐ This statement qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):

- ☐ (1) It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d)  
-- OR --  
☐ (2) It is being filed within 3 months of entry of a national stage  
-- OR --  
☐ (3) It is being filed before the mail date of the first Office Action on the merits  
-- OR --  
☐ (4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.


09/23/2005 MAHMED1 00000120 081641 09902572

01 FC:1806 180.00 DA

- ☐ 37 C.F.R. §1.97(c). If this statement is being filed after the latest of: (1) three months beyond the filing date of a national application; (2) three months beyond the date of entry of the national stage as set forth in §1.491 in an international application; or (3) the mailing date of a first Office action on the merits, but before the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, then:
- ☐ a certification as specified in §1.97(e) is provided below; or
- ☐ a fee of \$180.00 as set forth in §1.17(p) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ 37 C.F.R. §1.97(d). If this statement is being filed after the mailing date of the earlier of a final office action under §1.113 or a notice of allowance under §1.311, but before payment of the issue fee, then:
- A. a certification as specified in §1.97(e) is completed below; and
- B. a petition under 37 C.F.R. §1.97(d) requesting consideration of this statement is submitted herewith; **and**
- C. a fee of \$180.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included with the payment of other papers filed together with this statement.
- ☒ **Fee Authorization.** The Commissioner is hereby authorized to charge the above-referenced fees of **\$180.00** and charge any additional fees or credit any overpayment associated with this communication to Deposit Account No. 08-1641 (Docket No. 39780-1618P2C40).


Respectfully submitted,

Dated: September 19, 2005

By:   
Panpan Gao, REG. No. 43,626

**HELLER EHRMAN LLP**  
Customer No. 35489/09157  
275 Middlefield Road  
Menlo Park, CA 94025-3506  
Telephone: (650) 324-7000  
Facsimile: (650) 324-0638

<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>			<b>ATTY. DOCKET NO.</b> 39780-1618P2C40		<b>SERIAL NO.</b> 09/902,572	
			<b>APPLICANT</b> Ashkenazi et al.			
			<b>FILING DATE:</b> 07/10/01		<b>GROUP:</b> 1636	
<b>U.S. PATENT DOCUMENTS</b>						
<b>EXAMINER'S INITIALS</b>	<b>PATENT NO.</b>	<b>DATE</b>	<b>NAME</b>	<b>CLASS</b>	<b>SUBCLASS</b>	<b>FILING DATE</b>
	4,456,550	06/26/1994	Dvorak <i>et al.</i>	260	112	
	5,008,196	04/16/1991	Connolly <i>et al.</i>	435	240.2	
	5,036,003	07/30/1991	Olander <i>et al.</i>	435	70.1	
	5,240,848	08/31/1993	Keck <i>et al.</i>	435	240.2	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
	GenBank, Accession No.: P_AAF30502, WO 200119987, Pub Date: March 22, 2001, Fong <i>et al.</i> , "Composition comprising a PRO230, PRO216 or PRO302 polypeptide, agonist or antagonist for promoting or inhibiting angiogenesis and/or cardiovascularisation in mammals".					
	GenBank, Accession No.: P_AAA13199, WO 200015792-A2, Pub Date: March 23, 2000, Fong <i>et al.</i> , "A composition comprising PRO230, PRO216 or PRO302 polypeptides, agonists or antagonists useful for promotion or inhibition of cardiovascularisation, angiogenesis or endothelialisation in mammals".					
	GenBank, Accession No.: P_AAX52258, WO 9914328-A2, Pub Date: March 25, 1999, Chen <i>et al.</i> , "New isolated human genes and polypeptides used in, e.g. treatment of gastrointestinal ulceration".					
	GenBank, Accession No.: P_AAX25445, WO 9914234-A2, Pub Date: March 25, 1999, Fong <i>et al.</i> , "Composition comprising human polypeptides with anti-angiogenic activity".					
	GenBank, Accession No.: P_AAF72416, WO 200104311-A1, Pub Date: January 18, 2001, Ashkenazi <i>et al.</i> , "Sixty one nucleic acids encoding PRO polypeptides which are useful in the treatment of skin diseases, cancers and neurodegenerative diseases".					
	GenBank, Accession No.: P_ABL95586, WO 200208284-A2, Pub Date: January 18, 2001, Baker <i>et al.</i> , "One hundred and eighty seven nucleic acids encoding PRO polypeptides, useful in diagnosis and treatment of cardiovascular, endothelial or angiogenic disorders in a mammal".					
	GenBank, Accession No.: P_ABL88097, WO 200200690-A2, Pub Date: January 3, 2002, Baker <i>et al.</i> , "One hundred and eighty seven nucleic acids encoding PRO polypeptides, useful in diagnosis and treatment of cardiovascular, endothelial or angiogenic disorders in a mammal".					
	GenBank, Accession No.: AX098272, WO 0119987-A, Pub Date: March 22, 2001, Fong <i>et al.</i> , "Promotion or inhibition of angiogenesis and cardiovascularization".					
<b>EXAMINER</b>			<b>DATE CONSIDERED</b>			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.						



INFORMATION DISCLOSURE  
STATEMENT

PTO-1449

ATTY. DOCKET NO.

39780-1618P2C40

SERIAL NO.

09/902,572

APPLICANT Ashkenazi et al.

FILING DATE: 07/10/01

GROUP: 1636

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

GenBank, Accession No.: AX454466, WO 0208284-A, Pub Date: January 31, 2002, Baker *et al.*,  
"Composition and methods for the diagnosis and treatment of disorders involving angiogenesis".

GenBank, Accession No.: BD075577, JP 2001516580-A, Pub Date: October 2, 2001, Wood *et al.*,  
"Secretory and transmembrane polypeptide and nucleic acid encoding the same".

GenBank, Accession No.: BD173394, JP 2002238588-A, Pub Date: August 27, 2002, Wood *et al.*,  
"Secretory and transmembrane polypeptide and nucleic acid encoding the same".

GenBank, Accession No.: BD173075, JP 2002238587-A, Pub Date: August 27, 2002, Wood *et al.*,  
"Secretory and transmembrane polypeptide and nucleic acid encoding the same".

GenBank, Accession No.: AX490944; WO 0200690-A, Pub Date: January 3, 2002, Baker *et al.*,  
"Composition and methods for the diagnosis and treatment of disorders involving angiogenesis".

GenBank, Accession No.: BD172756, JP 2002238586-A, Pub Date: August 27, 2002, Wood *et al.*,  
"Secretory and transmembrane polypeptide and nucleic acid encoding the same".

GenBank, Accession No.: BD172437, JP 2002223786-A, Pub Date: August 13, 2002, Wood *et al.*,  
"Secretory and transmembrane polypeptide and nucleic acid encoding the same".

GenBank, Accession No.: BD175428, JP 2002253280-A, Pub Date: September 10, 2002, Wood *et al.*,  
"Secretory and transmembrane polypeptide and nucleic acid encoding the same".

GenBank, Accession No.: P\_ABV72656, WO 200268599-A2, Pub Date: September 6, 2002, Miano *et al.*,  
"New retinoid-inducible serine carboxypeptidase proteins and nucleic acids, useful for detecting or treating  
vascular diseases, e.g. vascular hyperplasia, atherosclerosis, asthma, glomerulonephritis, hypertension".

GenBank, Accession No.: P\_ABV77921, WO 200246465-A2, Pub Date: June 13, 2002, White *et al.*,  
"Identifying a gene involved in disease for treating hypoxia-regulated conditions, comprises comparing the  
transcriptome/ proteome of two cell types under different conditions and identifying a differentially  
regulated gene".

GenBank, Accession No.: AF282618, Direct Submission, Submitted: June 26, 2000, Cho *et al.*,  
Microbiology, Kyung Hee University, Hoeki 1, Seoul, Korea 130-701, Korea.


GenBank, Accession No.: NM\_021626, Chen *et al.*, "Cloning of a novel retinoid-inducible serine  
carboxypeptidase from vascular smooth muscle cells"; J. Biol. Chem. 276 (36), 34175-181 (2001).

GenBank, Accession No.: P\_AAH15579, EP 1074617-A2, Pub Date: February 7, 2001, Ota *et al.*, "Primer  
sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification,  
and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs."


EXAMINER

DATE CONSIDERED


EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and  
not considered. Include copy of this form with next communication to applicant.



<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>	<b>ATTY. DOCKET NO.</b> 39780-1618P2C40	<b>SERIAL NO.</b> 09/902,572
	<b>APPLICANT</b> Ashkenazi et al.	
	<b>FILING DATE:</b> 07/10/01	<b>GROUP:</b> 1636
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	GenBank, Accession No.: P_ABV28721, WO 200160860-A2, Pub Date: August 23, 2001, Schlegel <i>et al.</i> , "Novel isolated nucleic acid molecule associated with cancerous state of prostate cells and correlating with presence of prostate cancer, useful for detecting presence of prostate cancer, stage of prostate cancer".	
	GenBank, Accession No.: AK027373, Direct Submission, Submitted: May 10, 2001, Isogai <i>et al.</i> , Helix Research Institute, Genomics Laboratory, 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan.	
	GenBank, Accession No.: BD157571, JP 2002191363-A1, Pub Date: July 9, 2002, Ota <i>et al.</i> , "Primer for synthesizing full-length cDNA and use thereof".	
	GenBank, Accession No.: P_AAH72787, WO 200142467-A2, Pub Date: June 14, 2001, Schlegel <i>et al.</i> , "New isolated nucleic acid for diagnosing and treating cervical cancer and for assessing and detecting compounds for treating the cancer".	
	GenBank, Accession No.: AX188369, WO 0142467-A, Pub Date: June 14, 2001, Schlegel <i>et al.</i> , "Genes, compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer".	
	GenBank, Accession No.: P_AAD12590, WO 200149728-A2, Pub Date: July 12, 2001, Kato <i>et al.</i> , "Human proteins with hydrophobic domains and the nucleic acids encoding them, useful for preventing diagnosing and treating e.g. cancer, Alzheimer's and inflammation".	
	GenBank, Accession No.: AX191563, WO 0149728-A, Pub Date: July 12, 2001, Kato <i>et al.</i> , "Human proteins having hydrophobic domains and DNAs encoding these proteins".	
	GenBank, Accession No.: AF113214; Direct Submission, Submitted: December 15, 1998, Liu <i>et al.</i> , Molecular Medical Center for Cardiovascular Disease, Cardiovascular Institute, 167, Bei Li Shi Lu, Beijing 100037, P.R. China.	
	GenBank, Accession No.: P_AAC75884; WO 200058473-A2, Pub Date: October 5, 2000, Shimkets <i>et al.</i> , "Novel nucleic acids and peptides derived from open reading frame X, useful for treating e.g. cancers, proliferative disorders, neurodegenerative disorders and cardiovascular disease".	
	GenBank, Accession No.: P_ABK30363, US 6331427-B1, Pub Date: December 18, 2001, Robison, K. E.; "New polynucleotides encoding protease homologs of the G-protein-coupled protease family, useful in identifying agonists and antagonists for diagnosis and treatment of protease mediated disorders."	
	GenBank, Accession No.: P_AAH89926, WO200153453-A2, Pub Date: July 26, 2001, Ford <i>et al.</i> , "Novel bone-marrow-expressed polynucleotides and polypeptides, useful for treating e.g. cancer and immune deficiency disorders."	
	GenBank, Accession No.: AX191553, WO 0149728-A, Pub Date: July 12, 2001, Kato <i>et al.</i> , "Human proteins having hydrophobic domains and DNAs encoding these proteins."	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.		



<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>	<b>ATTY. DOCKET NO.</b> <b>39780-1618P2C40</b>	<b>SERIAL NO.</b> <b>09/902,572</b>
	<b>APPLICANT</b> Ashkenazi et al.	
	<b>FILING DATE:</b> 07/10/01	<b>GROUP:</b> 1636
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	Dayhoff, Accession No.: P_AAB84842, WO 200200690-A2, Pub Date: January 3, 2002, K. P. Baker <i>et al</i> , "One hundred and eighty seven nucleic acids encoding PRO polypeptides, useful in diagnosis and treatment of cardiovascular, endothelial or angiogenic disorders in a mammal".	
	Dayhoff, Accession No.: P_ABB95448, WO 200208284-A2, Pub Date: January 31, 2002, Baker <i>et al</i> , "One hundred and eighty seven nucleic acids encoding PRO polypeptides, useful in diagnosis and treatment of cardiovascular, endothelial or angiogenic disorders in a mammal."	
	Dayhoff, Accession No.: P_ABP65102; WO 200246465-A2, Pub Date: June 13, 2002, White <i>et al</i> , "Identifying a gene involved in disease for treating hypoxia-regulated conditions, comprises comparing the transcriptome/ proteome of two cell types under different conditions and identifying a differentially regulated gene".	
	Dayhoff, Accession No.: P_ABB99215, WO 200268599-A2. Pub Date: September 6, 2002, Miano <i>et al</i> , "New retinoid-inducible serine carboxypeptidase proteins and nucleic acids, useful for detecting or treating vascular diseases, e.g. vascular hyperplasia, atherosclerosis, asthma, glomerulonephritis, hypertension".	
	Dayhoff, Accession No.: P_AAB80255, WO 200104311-A1, Pub Date: January 18, 2001, Ashkenazi <i>et al</i> , "Sixty one nucleic acids encoding PRO polypeptides which are useful in the treatment of skin diseases, cancers and neurodegenerative diseases".	
	Dayhoff, Accession No.: P_AAB20341, WO 200119987-A1, Pub Date: March 22, 2001, Fong <i>et al</i> , "Composition comprising a PRO230, PRO216 or PRO302 polypeptide, agonist or antagonist for promoting or inhibiting angiogenesis and/or cardiovascularisation in mammals".	
	Dayhoff, Accession No.: P_AAB93913, EP1074617-A2, Pub Date: February 7, 2001, Ota <i>et al</i> , "Primer sets for synthesizing polynucleotides, particularly the 5602 full-length cDNAs defined in the specification, and for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs."	
	Dayhoff, Accession No.: P_AAE06595, WO 200149728-A2, Pub Date: July 12, 2001, Kato <i>et al</i> , "Human proteins with hydrophobic domains and the nucleic acids encoding them, useful for preventing diagnosing and treating e.g. cancer, Alzheimer's and inflammation".	
	Dayhoff, Accession No.: P_AAY88378, WO 200015792-A2, Pub Date: March 23, 2000, Fong <i>et al</i> , "Composition comprising a PRO230, PRO216 or PRO302 polypeptides, agonists or antagonists useful for promotion or inhibition of cardiovascularisation, angiogenesis or endothelialisation in mammals".	
	Dayhoff, Accession No.: P_AAY13387, WO 9914328-A2, Pub Date: March 25, 1999, Chen <i>et al</i> ; "New isolated human genes and polypeptides used in, e.g. treatment of gastrointestinal ulceration".	
<b>EXAMINER</b>	<b>DATE CONSIDERED</b>	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.		



<b>INFORMATION DISCLOSURE STATEMENT</b>  <b>PTO-1449</b>	<b>ATTY. DOCKET NO.</b> 39780-1618P2C40	<b>SERIAL NO.</b> 09/902,572
	<b>APPLICANT</b> Ashkenazi et al.	
	<b>FILING DATE:</b> 07/10/01	<b>GROUP:</b> 1636
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>		
	Dayhoff, Accession No.: P_AAY05768; WO 9914234-A2; Pub Date: March 25, 1999, Fong <i>et al.</i> , "Composition containing human polypeptides with anti-angiogenic activity".	
	Dayhoff, Accession No.: CAC51169.1, WO 0149728-A, Pub Date: July 12, 2001, Kato <i>et al.</i> , Human Proteins having hydrophobic domains and dnas encoding these proteins".	
	Dayhoff, Accession No.: AAG16692.1, Direct Submission, Submitted: June 26, 2000, Cho <i>et al.</i> , Microbiology, Kyung Hee University, Hoeki 1, Seoul, Korea.	
	Dayhoff, Accession No.: BAB55069.1, Direct Submission: May 10, 2001, Isogai <i>et al.</i> , Helix Research Institute, Genomics Laboratory, 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan.	
	Dayhoff, Accession No.: RISC_HUMAN, Direct Submission, Submitted: June 26, 2000, Cho <i>et al.</i> , "Cloning of novel serine carboxypeptidase precursor", Microbiology, Kyung Hee University, Hoeki 1, Seoul, Korea.	
	Dayhoff, Accession No.: P_AAU96225, WO 200224721-A1, Pub Date: March 28, 2002, Komatsoulis <i>et al.</i> , "Isolated nucleic acid molecules encoding a human secreted protein is used in preventing, treating or ameliorating a medical condition."	
	Dayhoff, Accession No.: P_AAB41675, WO 200058473-A2, Pub Date: October 5, 2000, Shimkets <i>et al.</i> , "Novel nucleic acids and peptides derived from open reading frame X, useful for treating e.g. cancers, proliferative disorders, neurodegenerative disorders and cardiovascular disease."	
	Dayhoff, Accession No.: AAG39285.1, Direct Submission, Submitted: December 15, 1998, Liu <i>et al.</i> , Molecular Medical Center for Cardiovascular Disease, Cardiovascular Institute, CAMS AND PUMC; 167, Bei Li Shi Lu, Beijing 100037, P.R. China.	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance <u>and</u> not considered. Include copy of this form with next communication to applicant.		

